2025 China Adult Vaccine Market Revenue Opportunities Report
Description
The 2025 China Adult Vaccine Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Adult Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the adult vaccine market in China are Pfizer, GlaxoSmithKline (GSK), Merck & Co., and Sanofi. Pfizer leverages mRNA and protein subunit technologies with strong R&D and manufacturing networks, making it a leader in adult vaccines like pneumococcal and meningococcal vaccines. GSK is notable for its diverse portfolio including shingles vaccine Shingrix, hepatitis, and influenza vaccines, with a significant presence in China through manufacturing and R&D hubs. Merck leads with vaccines including HPV (Gardasil) and hepatitis vaccines, emphasizing evidence-based development and global supply chains. Sanofi focuses on influenza, meningococcal, and combination vaccines, investing in innovative delivery platforms and manufacturing expansion.
Domestically, China’s vaccine market is dominated by large local companies such as Sinopharm Group, Sinovac Biotech, Walvax Biotechnology, and Beijing Tiantan Biological Products. These firms produce a large volume of vaccines annually and engage in the development and clinical trials of vaccines relevant to the adult population, including polysaccharide conjugate vaccines. Foreign companies like AstraZeneca are also heavily investing in R&D centers and vaccine manufacturing in China to strengthen their footprint. The local industry has grown competitive and innovates rapidly, with companies like Xiamen Innovax launching high-valency HPV vaccines, signaling expanding adult vaccine offerings within China itself.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Adult Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the adult vaccine market in China are Pfizer, GlaxoSmithKline (GSK), Merck & Co., and Sanofi. Pfizer leverages mRNA and protein subunit technologies with strong R&D and manufacturing networks, making it a leader in adult vaccines like pneumococcal and meningococcal vaccines. GSK is notable for its diverse portfolio including shingles vaccine Shingrix, hepatitis, and influenza vaccines, with a significant presence in China through manufacturing and R&D hubs. Merck leads with vaccines including HPV (Gardasil) and hepatitis vaccines, emphasizing evidence-based development and global supply chains. Sanofi focuses on influenza, meningococcal, and combination vaccines, investing in innovative delivery platforms and manufacturing expansion.
Domestically, China’s vaccine market is dominated by large local companies such as Sinopharm Group, Sinovac Biotech, Walvax Biotechnology, and Beijing Tiantan Biological Products. These firms produce a large volume of vaccines annually and engage in the development and clinical trials of vaccines relevant to the adult population, including polysaccharide conjugate vaccines. Foreign companies like AstraZeneca are also heavily investing in R&D centers and vaccine manufacturing in China to strengthen their footprint. The local industry has grown competitive and innovates rapidly, with companies like Xiamen Innovax launching high-valency HPV vaccines, signaling expanding adult vaccine offerings within China itself.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
